There are 2789 resources available
1510MO_PR - European cancer patients’ perspectives on Immunotherapy
Presenter: Paraskevas Kosmidis
Session: Mini oral session - Public policy
Resources:
Abstract
Slides
Webcast
228MO - PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)
Presenter: Binghe Xu
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
229MO - Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
Presenter: Miguel Martin Jimenez
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
230MO - First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies
Presenter: Matthew Krebs
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Polling 2 (led by chair)
Presenter: Florence Joly
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
Q&A
Presenter: Florence Joly
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Florence Joly
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
Yes
Presenter: Isabelle Ray-Coquard
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
No
Presenter: Antonio Jose Gonzalez Martin
Session: Should we test our patients in clinical practice with HRD? How and when?
Resources:
Slides
Webcast
Optimal selection of patients with untreated advanced renal carcinoma for combination and monotherapy regimens: Agents, combinations and emerging biomarkers
Presenter: Jens Bedke
Session: ESMO Colloquium supported by Eisai Europe Ltd - How to optimise efficacy and safety of targeted agent/IO management strategies in advanced solid tumours: Single agents, combinations and biomarkers
Resources:
Slides
Webcast